NDDS in Cancer Therapy Market by Type, Mode, Route of Administration, Application, End-User - Global Forecast 2025-2030- Product Image

Sale

NDDS in Cancer Therapy Market by Type, Mode, Route of Administration, Application, End-User - Global Forecast 2025-2030

Report
193 Pages
October 2024
Region: Global
360iResearch™
ID: 5888824

UP TO €681EUR$697USD£568GBP OFF until Dec 31^st 2024

The NDDS in Cancer Therapy Market grew from USD 10.41 billion in 2023 to USD 11.75 billion in 2024. It is expected to continue growing at a CAGR of 13.28%, reaching USD 24.94 billion by 2030.

The development and expansion of Novel Drug Delivery Systems (NDDS) in cancer therapy offer a promising field, encompassing innovative techniques to improve drug efficacy, safety, and patient compliance. Defined as advanced methods for delivering therapeutic agents to enhance treatment effectiveness and reduce side effects, NDDS includes nanoparticles, liposomes, and conjugates that enable targeted drug delivery directly to cancer cells. The necessity arises from the limitations of traditional chemotherapy and radiotherapy, which often affect healthy cells and cause significant side effects. NDDS applications are broad, from personalized medicine and precision oncology to less invasive treatment options providing enhanced patient quality of life. The end-use scope is vast, spanning hospitals, cancer treatment centers, and research institutions keen on advancements in therapeutic options.

Market insights underscore factors such as rising cancer incidences, technological advancements, and increased funding for cancer research as primary growth drivers. Potential opportunities lie in the increased demand for targeted and personalized healthcare, particularly in emerging economies where healthcare infrastructure is developing rapidly. Recommendations for seizing these opportunities include strategic partnerships with research institutions and investment in R&D to innovate and enhance NDDS platforms.

However, market growth faces limitations like high development costs, regulatory challenges, and potential side effects of new delivery systems. Intellectual property issues and the complexity of manufacturing processes also pose significant challenges. Areas ripe for innovation and research include the development of biodegradable nanoparticles, advancements in gene delivery systems, and the integration of artificial intelligence for patient-specific treatment plans.

The nature of the NDDS market in cancer therapy is dynamic, reflecting both the evolving landscape of medical science and the urgent demand for more effective cancer treatments. Companies that can successfully navigate regulatory environments, secure intellectual property, and foster collaborative innovation will be well-positioned for growth and leadership in this burgeoning market.

Understanding Market Dynamics in the NDDS in Cancer Therapy Market

The NDDS in Cancer Therapy Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Rising prevalence of cancer across the globe
- Increasing need of NDDS to imrove drug solubility and reduce toxicity
- Accelerating investments for development of novel drug delivery systems for cancer
Market Restraints
- Limited awareness and involvement of huge cost
Market Opportunities
- Emerging government initiatives coupled with favorable reimbursement policies
- Ongoing research activities for advanced anti-cancer nano drug delivery system
Market Challenges
- Dearth of skilled and experienced medical professionals

Exploring Porter’s Five Forces for the NDDS in Cancer Therapy Market

Porter’s Five Forces framework further strengthens the insights of the NDDS in Cancer Therapy Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the NDDS in Cancer Therapy Market

External macro-environmental factors deeply influence the performance of the NDDS in Cancer Therapy Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the NDDS in Cancer Therapy Market

The NDDS in Cancer Therapy Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the NDDS in Cancer Therapy Market

The NDDS in Cancer Therapy Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the NDDS in Cancer Therapy Market

The NDDS in Cancer Therapy Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the NDDS in Cancer Therapy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca, Boston Scientific Corporation, Cospheric LLC, Enable Injections, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Merit Medical Systems, MO-SCI Corporation, Novartis AG, Pacira BioSciences, Inc., Pfizer Inc., Samyang Holdings Corporation, Sanofi S.A., Teva Pharmaceutical Industries Ltd., and West Pharmaceutical Services, Inc..

Market Segmentation & Coverage

This research report categorizes the NDDS in Cancer Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Dendrimers
- Liposomes
- Micelles
- Nanoparticles
Mode
- Controlled Drug Delivery Systems
- Modulated Drug Delivery Systems
- Targeted Drug Delivery Systems
Route of Administration
- Injectable Drug Delivery Systems
- Oral Drug Delivery Systems
- Pulmonary Drug Delivery Systems
- Transdermal Drug Delivery Systems
Application
- Brain Cancer
- Breast Cancer
- Lung Cancer
- Pancreatic Cancer
End-User
- Ambulatory Surgical Centers
- Hospitals
- Specialty Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cancer across the globe
5.1.1.2. Increasing need of NDDS to imrove drug solubility and reduce toxicity
5.1.1.3. Accelerating investments for development of novel drug delivery systems for cancer
5.1.2. Restraints
5.1.2.1. Limited awareness and involvement of huge cost
5.1.3. Opportunities
5.1.3.1. Emerging government initiatives coupled with favorable reimbursement policies
5.1.3.2. Ongoing research activities for advanced anti-cancer nano drug delivery system
5.1.4. Challenges
5.1.4.1. Dearth of skilled and experienced medical professionals
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. NDDS in Cancer Therapy Market, by Type

6.1. Introduction
6.2. Dendrimers
6.3. Liposomes
6.4. Micelles
6.5. Nanoparticles

7. NDDS in Cancer Therapy Market, by Mode

7.1. Introduction
7.2. Controlled Drug Delivery Systems
7.3. Modulated Drug Delivery Systems
7.4. Targeted Drug Delivery Systems

8. NDDS in Cancer Therapy Market, by Route of Administration

8.1. Introduction
8.2. Injectable Drug Delivery Systems
8.3. Oral Drug Delivery Systems
8.4. Pulmonary Drug Delivery Systems
8.5. Transdermal Drug Delivery Systems

9. NDDS in Cancer Therapy Market, by Application

9.1. Introduction
9.2. Brain Cancer
9.3. Breast Cancer
9.4. Lung Cancer
9.5. Pancreatic Cancer

10. NDDS in Cancer Therapy Market, by End-User

10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Hospitals
10.4. Specialty Clinics

11. Americas NDDS in Cancer Therapy Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific NDDS in Cancer Therapy Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa NDDS in Cancer Therapy Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. NDDS IN CANCER THERAPY MARKET RESEARCH PROCESS
FIGURE 2. NDDS IN CANCER THERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 19. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. NDDS IN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 25. NDDS IN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. NDDS IN CANCER THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. NDDS IN CANCER THERAPY MARKET DYNAMICS
TABLE 7. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY CONTROLLED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MODULATED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY ORAL DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PULMONARY DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TRANSDERMAL DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY BRAIN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 48. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. CANADA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 53. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. MEXICO NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 75. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 80. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. INDIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 89. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 90. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. JAPAN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 119. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 120. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. THAILAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 134. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 136. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. DENMARK NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 140. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 141. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. EGYPT NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 145. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 146. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. FINLAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 149. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 150. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 151. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. FRANCE NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 155. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 156. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 158. GERMANY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 165. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 166. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. ITALY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 180. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 181. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 182. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. NORWAY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 184. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 185. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 186. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. POLAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 189. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 190. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 191. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. QATAR NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 209. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 210. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 211. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 213. SPAIN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 224. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 225. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 226. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. TURKEY NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY MODE, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM NDDS IN CANCER THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 239. NDDS IN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2023
TABLE 240. NDDS IN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the NDDS in Cancer Therapy Market, which are profiled in this report, include:

Abbott Laboratories
AstraZeneca
Boston Scientific Corporation
Cospheric LLC
Enable Injections
GlaxoSmithKline PLC
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Merit Medical Systems
MO-SCI Corporation
Novartis AG
Pacira BioSciences, Inc.
Pfizer Inc.
Samyang Holdings Corporation
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
West Pharmaceutical Services, Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	193
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 11.75 Billion
Forecasted Market Value ( USD ) by 2030	$ 24.94 Billion
Compound Annual Growth Rate	13.2%
Regions Covered	Global
No. of Companies Mentioned	17

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3464EUR$3,545USD£2,892GBP €3849EUR$3,939USD£3,213GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6128EUR$6,272USD£5,116GBP €6809EUR$6,969USD£5,684GBP

Understanding Market Dynamics in the NDDS in Cancer Therapy Market

Exploring Porter’s Five Forces for the NDDS in Cancer Therapy Market

Applying PESTLE Analysis to the NDDS in Cancer Therapy Market

Analyzing Market Share in the NDDS in Cancer Therapy Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the NDDS in Cancer Therapy Market

Strategic Recommendations for Success in the NDDS in Cancer Therapy Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

NDDS in Cancer Therapy - Global Strategic Business Report

Cancer Drugs Market by Route of Administration, Type of Therapy, Type, End-User - Global Forecast 2025-2030

Cancer Biological Therapy Market by Product, Route of Administration, End-Users - Global Forecast 2025-2030

Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy), By Route Of Administration (Injectable, Oral), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy), By End-use (Research Institutes, Biopharmaceutical Companies), By Region, And Segment Forecasts, 2024 - 2030